Showing results (941-950 of 3,376) with videos related to

Sort By:
Pageof 338
The Lancet. Oncology|March 10, 2022
Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysisKerstin N Vokinger, Thomas J Hwang, David L Carl, et al.
The Lancet. Oncology|May 12, 2019
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trialIgnace Vergote, Giovanni Scambia, David M O'Malley, et al.
The Lancet. Oncology|July 4, 2019
Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancersLajos Pusztai, Julia Foldi, Arjun Dhawan, et al.
The Lancet. Oncology|January 14, 2023
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort studyCédric Nesti, Konstantin Bräutigam, Marta Benavent, et al.
The Lancet. Oncology|May 19, 2015
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trialMichael R Migden, Alexander Guminski, Ralf Gutzmer, et al.
The Lancet. Oncology|May 19, 2015
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialJin Li, Shukui Qin, Ruihua Xu, et al.
The Lancet. Oncology|May 12, 2015
Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysisCezary Cybulski, Wojciech Kluźniak, Tomasz Huzarski, et al.
The Lancet. Oncology|May 12, 2015
Parenthood in adult female survivors treated for Hodgkin's lymphoma during childhood and adolescence: a prospective, longitudinal studyJürgen H Brämswig, Marianne Riepenhausen, Günther Schellong
The Lancet. Oncology|May 7, 2015
Tackling cancer control in the Gulf Cooperation Council CountriesSaleh Al-Othman, Abdelali Haoudi, Samar Alhomoud, et al.
The Lancet. Oncology|May 1, 2015
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 studyMaria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, et al.
Pageof 338